According to the ILTE (Imatinib Long Term Evaluation) study, CML patients who under imatinib therapy have achieved complete cytogenetic remission and are still in CCyR after to years of therapy, have a life expectancy similar to the o control population without leukemia. If this patients were also able to achieve CMR and to remain in CMR for at least 2 years, they have also the possibility to try to discontinue the treatment with an expected rate of successful discontinuation of approximately 40%. Longer the period of TKI therapy and of assessed CMR, however, higher the probability of successful discontinuation. Several clinical trials are presently ongoing to establish the optimal conditions allowing treatment discontinuation and it is recommended to enter one of such protocols in the attempt to try to discontinue the therapy or at least to do it under strict control of the hematologist of reference.